Hively Brad
SEC CIK 1891124 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| STLN | Starling Oncology, Inc. | Dir | 412.0K | $106.5K | $7.94M | 28 | 2021-01-12 | 2026-08-21 |
Most active insiders at STLN, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Chernett Jorey | 10% | $2.69M | — |
| 2 | Hively Brad | Dir | — | $2.00M |
| 3 | Kaushal Mohit | Dir | — | $335.1K |
| 4 | Podnos Yale | Chief Medical Off | — | $276.4K |
| 5 | Pacala Mark L | Dir | — | $200.0K |
| 6 | Carter Robert Ross | CFO | — | $879.32 |
| 7 | England Kristin | Chief Administrative Off | — | — |
| 8 | Langsam Jeffrey | Chief Clinical Off | — | — |
| 9 | Ling Gabriel | Dir | — | — |
| 10 | TOI M, LLC | Dir | — | — |
Transactions 28
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-08-24 17:11 | 2026-08-21 | STLN | Starling Oncology, Inc. | Hively Brad | Dir | S - Sale | $6.51 | -298.9K | 412.0K | -42% | -$1.95M |
| 2026-07-29 18:49 | 2026-07-27 | STLN | Starling Oncology, Inc. | Hively Brad | Dir | A - Grant | $0.00 | +27.1K | 710.8K | +4% | $0 | |
| 2025-12-16 | 2025-12-15 | STLN | Starling Oncology, Inc. | Hively Brad | Dir | S - Sale | $3.77 | -13.3K | 683.7K | -2% | -$50.3K | |
| M | 2025-11-24 | 2025-11-20 | STLN | Starling Oncology, Inc. | Hively Brad | Dir | A - Grant | $0.00 | +74.1K | 664.6K | +13% | $0 |
| 2025-08-21 | 2025-08-19 | STLN | Starling Oncology, Inc. | Hively Brad | Dir | S - Sale | $4.06 | -20.2K | 623.0K | -3% | -$82.1K | |
| DM | 2025-06-05 | 2025-06-03 | STLN | Starling Oncology, Inc. | Hively Brad | Dir | S - Sale+OE | $2.87 | -1.98M | 712.0K | -74% | -$5.67M |
| DM | 2025-06-05 | 2025-06-03 | STLN | Starling Oncology, Inc. | Hively Brad | Dir | M - OptEx | $0.9008 | +1.87M | 1.40M | New | +$1.68M |
| DA | 2025-04-28 | 2025-03-26 | STLN | Starling Oncology, Inc. | Hively Brad | Dir | P - Purchase | $1.04 | +45.3K | 712.0K | +7% | +$47.1K |
| D | 2025-03-28 | 2025-03-26 | STLN | Starling Oncology, Inc. | Hively Brad | Dir | P - Purchase | $1.04 | +9,056 | 675.8K | +1% | +$9,418 |
| M | 2024-12-02 | 2024-11-26+ | STLN | Starling Oncology, Inc. | Hively Brad | Dir | P - Purchase | $0.1667 | +300.0K | 616.8K | +95% | +$50.0K |
| 2024-12-02 | 2024-11-12 | STLN | Starling Oncology, Inc. | Hively Brad | Dir | J - Other | $0.00 | -353.4K | 366.8K | -49% | $0 | |
| 2024-11-25 | 2024-11-22 | STLN | Starling Oncology, Inc. | Hively Brad | Dir | A - Grant | $0.00 | +44.0K | 720.2K | +7% | $0 | |
| 2024-06-20 | 2024-06-17 | STLN | Starling Oncology, Inc. | Hively Brad | Dir | D - Sale to Iss | $0.46 | -18.1K | 676.2K | -3% | -$8,336 | |
| 2024-05-23 | 2024-05-22 | STLN | Starling Oncology, Inc. | Hively Brad | Dir | D - Sale to Iss | $0.58 | -19.5K | 694.3K | -3% | -$11.3K | |
| 2023-12-28 | 2023-12-26 | STLN | Starling Oncology, Inc. | Hively Brad | Dir | A - Grant | $0.00 | +42.7K | 713.9K | +6% | $0 | |
| 2023-11-22 | 2023-11-21 | STLN | Starling Oncology, Inc. | Hively Brad | Dir | D - Sale to Iss | $2.19 | -25.9K | 671.2K | -4% | -$56.6K | |
| D | 2023-11-21 | 2023-11-17 | STLN | Starling Oncology, Inc. | Hively Brad | Dir | S - Sale+OE | $2.24 | -25.0K | 697.1K | -3% | -$56.0K |
| D | 2023-11-21 | 2023-11-17 | STLN | Starling Oncology, Inc. | Hively Brad | Dir | M - OptEx | $0.85 | +25.0K | 722.1K | +4% | +$21.2K |
| D | 2023-11-15 | 2023-11-13 | STLN | Starling Oncology, Inc. | Hively Brad | Dir | S - Sale+OE | $2.52 | -47.0K | 724.2K | -6% | -$118.4K |
| D | 2023-11-15 | 2023-11-13 | STLN | Starling Oncology, Inc. | Hively Brad | Dir | M - OptEx | $0.85 | +47.0K | 771.2K | +6% | +$40.0K |
| D | 2023-11-15 | 2023-11-14 | STLN | Starling Oncology, Inc. | Hively Brad | Dir | D - Sale to Iss | $2.39 | -27.1K | 697.1K | -4% | -$64.8K |
| D | 2023-03-21 | 2023-03-17 | STLN | Starling Oncology, Inc. | Hively Brad | CEO, Dir | A - Grant | $0.00 | +168.5K | 724.2K | +30% | $0 |
| A | 2022-11-22 | 2022-11-15 | STLN | Starling Oncology, Inc. | Hively Brad | CEO | S - Sale | $2.03 | -9,718 | 452.2K | -2% | -$19.7K |
| D | 2022-11-21 | 2022-11-17 | STLN | Starling Oncology, Inc. | Hively Brad | CEO | A - Grant | $0.00 | +103.5K | 555.7K | +23% | $0 |
| 2022-11-17 | 2022-11-15 | STLN | Starling Oncology, Inc. | Hively Brad | CEO | D - Sale to Iss | $2.03 | -9,718 | 452.2K | -2% | -$19.7K | |
| D | 2022-03-23 | 2022-03-21 | STLN | Starling Oncology, Inc. | Hively Brad | CEO, Dir | A - Grant | $0.00 | +108.5K | 461.9K | +31% | $0 |
| MA | 2021-11-18 | 2021-11-12 | STLN | Starling Oncology, Inc. | Hively Brad | CEO, Dir | A - Grant | $0.00 | +353.4K | 363.4K | +3,534% | $0 |
| DM | 2021-11-16 | 2021-01-12 | STLN | Starling Oncology, Inc. | Hively Brad | CEO, Dir | A - Grant | $0.00 | +353.4K | 141.4K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations